51
|
Furuse M, Miyatake SI, Miyata T, Yoritsune E, Kawabata S, Kuroiwa T, Karajannis MA, Fisher MJ, Milla SS, Cohen KJ, Legault G, Wisoff JH, Harter DH, Hartnett E, Merkelson A, Bloom MC, Dhall G, Jones D, Korshunov A, Pfister S, Eberhart CG, Zagzag D, Allen JC, Chinot O, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Hilton M, Abrey L, Cloughesy T, Field KM, Simes J, Nowak AK, Hovey E, Wheeler H, Cher L, Brown C, Livingstone A, Sawkins K, Rosenthal MA, McCrea HJ, Kesavabhotla K, Boockvar J, Kleinberg L, Blakeley J, Mikkelsen T, Stevens G, Ye X, Ryu S, Desideri S, Desai B, Giranda V, Grossman S, Badruddoja MA, Pazzi M, Stea B, Lefferts P, Contreras N, Wallen K, Shah R, Rance N, Schroeder K, Sanan A, Kut C, Raza S, Liang W, Abutaleb A, Xi J, Mavadia J, Ye X, Guerrero-Cazares H, McVeigh E, Li X, Quinones-Hinojosa A, Sloan AE, Reese J, Rogers LR, Embree H, Lazarus HM, Fung H, Kane D, Dropulic B, Gerson SL, Tsung GE, Green SD, Lai A, Green RM, Filka E, Cloughesy TF, Nghiemphu PL, Saito R, Yamashita Y, Sonoda Y, Kanamori M, Kumabe T, Tominaga T, Mohammadi AM, Chao ST, Peereboom DM, Barnett GH, Suh JH, Brewer C, Vogelbaum MA, Desjardins A, Peters KB, Herndon JE, Bailey LA, Alderson LM, Ranjan T, Sampson JH, Friedman AH, Bigner DD, Friedman HS, Vredenburgh JJ, Kaley TJ, Pentsova E, Omuro A, Mellinghoff I, Nolan C, Gavrilovic I, DeAngelis LM, Holland E, Lacouture ME, Ludwig E, Lassman AB, Shih KC, Bacha J, Brown DM, Garner WJ, Schwartz R, Burris HA, Shih K, Rosenblatt P, Chowdhary S, Weir A, Shepard G, Shastry M, Griner P, Hainsworth J, Sloan AE, Nock CJ, Kerstetter A, Supko J, Ye X, Barnholtz-Sloan JS, Miller R, Rich J, Takebe N, Prados M, Grossman S. CLIN-ONGOING CLINICAL TRIALS. Neuro Oncol 2012; 14:vi101-vi105. [PMCID: PMC3488786 DOI: 10.1093/neuonc/nos232] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/24/2023] Open
|
52
|
Kozono D, Nitta M, Sampetrean O, Kimberly N, Kushwaha D, Merzon D, Ligon K, Zhu S, Zhu K, Kim TH, Kwon CH, Becher O, Saya H, Chen CC, Donovan LK, Birks SM, Bosak V, Pilkington GJ, Mao P, Li J, Joshi K, Hu B, Cheng S, Sobol RW, Nakano I, Li M, Hale JS, Myers JT, Huang AY, Gladson C, Sloan AA, Rich JN, Lathia JD, Hall PE, Li M, Gallagher J, Hale JS, Wu Q, Venere M, Levy E, Rani MS, Huang P, Bae E, Selfridge J, Cheng L, Guvenc H, McLendon RE, Nakano I, Sloan AE, Phillips H, Lai A, Gladson C, Bredel M, Bao S, Hjelmeland A, Lathia JD, Rich JN, Hale JS, Li M, Sinyuk M, Rich JN, Lathia JD, Lathia JD, Li M, Sathyan P, Hale J, Zinn P, Gallagher J, Wu Q, Carson CT, Naik U, Hjelmeland A, Majumder S, Rich JN, Venere M, Wu Q, Song LA, Vasanji A, Tenley N, Hjelmeland AB, Rich JN, Peruzzi P, Bronisz A, Antonio Chiocca E, Godlewski JA, Guryanova OA, Wu Q, Fang X, Rich JN, Bao S, Christel HMC, Benito C, Zoltan G, Aline B, Tilman S, Josephine B, Carolin M, Thomas S, Violaine G, Unterberg A, Capilla-Gonzalez V, Guerrero-Cazares H, Cebrian-Silla A, Garcia-Verdugo JM, Quinones-Hinojosa A, Man J, Shoemake J, Venere M, Rich J, Yu J, He X, DiMeco F, Vescovi AL, Heth JA, Muraszko KM, Fan X, Nguyen SA, Stechishin OD, Luchman HA, Kelly JJ, Cairncross JG, Weiss S, Kim Y, Kim E, Wu Q, Guryanova OO, Hitomi M, Lathia J, Serwanski D, Sloan AE, Robert J, Lee J, Nishiyama A, Bao S, Hjelmeland AB, Rich JN, Liu JK, Wu Q, Hjelmeland AB, Rich JN, Flavahan WA, Kim Y, Li M, Lathia J, Rich J, Hjelmeland A, Fernandez N, Wu M, Bredel M, Das S, Bazzoli E, Pulvirenti T, Oberstadt MC, Perna F, Boyoung W, Schultz N, Huse JT, Fomchenko EI, Voza F, Tabar V, Brennan CW, DeAngelis LM, Nimer SD, Holland EC, Squatrito M, Chen YH, Gutmann DH, Kim SH, Lee MK, Chwae YJ, Yoo BC, Kim KH, Soeda A, Hara A, Iwama T, Park DM, Golebiewska A, Bougnaud S, Stieber D, Brons NH, Vallar L, Hertel F, Bjerkvig R, Niclou SP, Hamerlik P, Lathia JD, Rasmussen R, Fricova D, Rich JN, Jiri B, Schulte A, Kathagen A, Zapf S, Meissner H, Phillips HS, Westphal M, Lamszus K, Sanzey M, Golebiewska A, Stieber D, Niclou SP, Singh SK, Vartanian A, Gumin J, Sulman EP, Lang FF, Zadeh G, Bayin NS, Dietrich A, Abel T, Chao MV, Song HR, Buchholz CJ, Placantonakis D, Esencay M, Zagzag D, Balyasnikova IV, Prasol MS, Ferguson SD, Ahmed AU, Han Y, Lesniak MS, Barish ME, Brown CE, Herrmann K, Argalian S, Gutova M, Tang Y, Annala A, Moats RA, Ghoda LY, Aboody KS, Hitomi M, Gallagher J, Gadani S, Li M, Adkins J, Vsanji A, Wu Q, Soeda A, McLendon R, Chenn A, Hjelmeland A, Park D, Lathia J, Rich J, Dictus C, Friauf S, Valous NA, Grabe N, Muerle B, Unterberg AW, Herold-Mende CC, Lee HK, Finniss S, Buchris E, Ziv-Av A, Casacu S, Xiang C, Bobbit K, Rempel SA, Mikkelsen T, Slavin S, Brodie C, Kim E, Woo DH, Oh Y, Kim M, Nam DH, Lee J, Li Q, Salas S, Pendleton C, Wijesekera O, Chesler D, Wang J, Smith C, Guerrero-Cazares H, Levchenko A, Quinones-Hinojosa A, LaPlant Q, Pitter K, Bleau AM, Helmy K, Werbeck J, Barrett L, Shimizu F, Benezra R, Tabar V, Holland E, Chu Q, Bar E, Orr B, Eberhart CG, Schmid RS, Bash RE, Werneke AM, White KK, Miller CR, Agasse F, Jhaveri N, Hofman FM, Chen TC, Natsume A, Wakabayashi T, Kondo Y, Woo DH, Kim E, Chang N, Nam DH, Lee J, Moon E, Kanai R, Yip S, Kimura A, Tanaka S, Rheinbay E, Cahill D, Curry W, Mohapatra G, Iafrate J, Chi A, Martuza R, Rabkin S, Wakimoto H, Cusulin C, Luchman HA, Weiss S, Gutova M, Frank JA, Annala AJ, Barish ME, Moats RA, Aboody KS. LAB-STEM CELLS. Neuro Oncol 2012. [DOI: 10.1093/neuonc/nos239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
53
|
Abstract
Glioblastoma, the most common malignant primary brain tumor, carries an invariably poor prognosis. Targeting underlying biological foundations of the disease will be crucial to developing more effective treatment strategies. Although increasing evidence clearly indicates that glioblastoma is a molecularly heterogeneous disorder, recent large-scale expression profiling has provided a framework for categorizing the tumor into 3 to 4 distinct subclasses, each with its own characteristic genomic alterations. As such, there remains the enticing possibility that glioblastoma subclasses themselves might represent predictive biomarkers, particularly in the context of specific targeted agents. This review focuses on how best to ascertain the functional relevance of molecular subclass in glioblastoma through both preclinical and clinical investigations. The availability of appropriate mouse modeling systems along with expanded molecular profiling capabilities in the clinical setting should aid such efforts. However, significant systematic challenges remain, particularly in the setting of clinical trials.
Collapse
|
54
|
Haslam N, Holland E, Kuppens P. Categories versus dimensions in personality and psychopathology: a quantitative review of taxometric research. Psychol Med 2012; 42:903-920. [PMID: 21939592 DOI: 10.1017/s0033291711001966] [Citation(s) in RCA: 289] [Impact Index Per Article: 24.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Taxometric research methods were developed by Paul Meehl and colleagues to distinguish between categorical and dimensional models of latent variables. We have conducted a comprehensive review of published taxometric research that included 177 articles, 311 distinct findings and a combined sample of 533 377 participants. Multilevel logistic regression analyses have examined the methodological and substantive variables associated with taxonic (categorical) findings. Although 38.9% of findings were taxonic, these findings were much less frequent in more recent and methodologically stronger studies, and in those reporting comparative fit indices based on simulated comparison data. When these and other possible confounds were statistically controlled, the true prevalence of taxonic findings was estimated at 14%. The domains of normal personality, mood disorders, anxiety disorders, eating disorders, externalizing disorders, and personality disorders (PDs) other than schizotypal yielded little persuasive evidence of taxa. Promising but still not definitive evidence of psychological taxa was confined to the domains of schizotypy, substance use disorders and autism. This review indicates that most latent variables of interest to psychiatrists and personality and clinical psychologists are dimensional, and that many influential taxonic findings of early taxometric research are likely to be spurious.
Collapse
|
55
|
MacGregor S, Brown KM, Stark M, Gartside M, Woods S, Bonazzi V, Aoude L, Dutton-Regester K, Tyagi S, Liu J, Duffy DL, Palmer J, Cust A, Schmid H, Symmons J, Holland E, Agha-Hamilton C, Holohan K, Youngkin D, Gillanders E, Jenkins MA, Kelly J, Whiteman DC, Kefford R, Giles G, Armstrong B, Aitken J, Hopper J, Montgomery G, Schmidt C, Trent JM, Martin NG, Mann GJ, Hayward NK. From GWAS to genome sequencing: complementary approaches to identify melanoma predisposition genes. Hered Cancer Clin Pract 2012. [PMCID: PMC3327126 DOI: 10.1186/1897-4287-10-s2-a46] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
|
56
|
He H, Emmett MR, Marshall AG, Ji Y, Conrad CA, Priebe W, Colman H, Lang FF, Madden TL, Kristoffersen K, Stockhausen MT, Poulsen HS, Binder ZA, Orr B, Lim M, Weingart JD, Brem H, Olivi A, Riggins GJ, Gallia GL, Litofsky NS, Miller DC, Rath P, Anthony DC, Feng Q, Franklin C, Pei L, Free A, Kirk MD, Shi H, Timmer M, Theiss H, Juerchott K, Ries C, Paron I, Franz W, Selbig J, Guo K, Tonn JC, Schichor C, Zhou YH, Hu Y, Pioli PD, Rajneesh K, Limoli CL, Yu L, Hess KR, Linskey ME, Faber F, Guo K, Jaeger D, Thorsteinsdottir J, Albrecht V, Tonn JC, Schichor C, Price R, Song J, Zimmerman P, Duale H, Rivera A, Kaur B, Parada L, Cook C, Chiocca EA, Kwon CH, Munoz DM, Guha A, Estrada-Bernal A, Van Brocklyn JR, Gu C, Mahasenan KV, Joshi K, Gupta S, Mattson A, Li C, Nakano I, Chi AS, Rheinbay E, Wakimoto H, Gillespie S, Kasif S, Rabkin SD, Martuza RL, Bernstein BE, Skirboll SL, Wurdak H, Zhu S, Romero A, Lorger M, Watson J, Chiang CY, Zhang J, Natu VS, Lairson LL, Walker JR, Trussell CM, Harsh GR, Vogel H, Felding-Habermann B, Orth AP, Miraglia LJ, Rines DR, Schultz PG, Hide T, Takezaki T, Nakamura H, Makino K, Kuratsu JI, Kondo T, Yao J, Kim YW, Koul D, Almeida JS, Weinstein JN, Alfred Yung WK, Joshi K, Miyazaki T, Chaudhury AR, Nakano I, Wong AJ, Del Vecchio C, Mitra S, Han SY, Holgado-Madruga M, Gupta P, Golebiewska A, Brons NH, Bjerkvig R, Niclou SP, Ramm P, Vollmann-Zwerenz A, Beier C, Aigner L, Bogdahn U, Kalbitzer HR, Hau P, Sanzey M, Golebiewska A, Vallar L, Niclou SP, Tamura K, Aoyagi M, Ando N, Ogishima T, Wakimoto H, Yamamoto M, Ohno K, Perin A, Fung KH, Longatti P, Guiot MC, Del Maestro RF, Rossi S, Stechishin O, Weiss S, Stifani S, Goodman L, Gao F, Gumin J, Ezhilarasan R, Love P, George A, Colman H, Lang F, Aldape K, Sulman EP, Soeda A, Lee DH, Shaffrey ME, Oldfield EH, Park DM, Dietrich J, Han R, Noble M, Yang MY, Liu X, Madhankumar AB, Sheehan J, Slagle-Webb B, Connor JR, Fu J, Shen RJ, Colman H, Lang FF, Alfred Yung WK, Koul D, Kaluzova M, Machaidze R, Nduom ENK, Burden CT, Hadjipanayis CG, Lei L, Sonabend A, Guarnieri P, Ludwig T, Rosenfeld S, Bruce J, Canoll P, Vaillant BD, Bhat K, Balasubramaniyam V, Wang S, Gumin J, Sulman E, Lang F, Aldape K, Colman H, Sulman EP, Ezhilarasan R, Goodman LD, Love PN, George A, Aldape K, Soules M, Zhu T, Flack C, Talsma C, Hamm L, Muraszko K, Fan X, Aoyagi M, Matsuoka Y, Tamura K, Ando N, Kawano Y, Ohno K, Kobayashi D, Kumagai J, Frank RT, Najbauer J, Aboody KS, Aboody KS, Najbauer J, Metz M, Garcia E, Aramburo S, Valenzuela V, Gutova M, Annala AJ, Barish M, Danks M, Kim SU, Portnow J, Hofstetter C, Gursel D, Mubita L, Holland E, Boockvar J, Monje M, Freret M, Masek M, Edwards MS, Fisher PG, Vogel H, Beachy P. Stem Cells. Neuro Oncol 2010. [DOI: 10.1093/neuonc/noq116.s18] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
57
|
Vitousek PM, Naylor R, Crews T, David MB, Drinkwater LE, Holland E, Johnes PJ, Katzenberger J, Martinelli LA, Matson PA, Nziguheba G, Ojima D, Palm CA, Robertson GP, Sanchez PA, Townsend AR, Zhang FS. Response—Nutrient Imbalances. Science 2009. [DOI: 10.1126/science.326_665c] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
58
|
Vitousek PM, Naylor R, Crews T, David MB, Drinkwater LE, Holland E, Johnes PJ, Katzenberger J, Martinelli LA, Matson PA, Nziguheba G, Ojima D, Palm CA, Robertson GP, Sanchez PA, Townsend AR, Zhang FS. Agriculture. Nutrient imbalances in agricultural development. Science 2009. [PMID: 19541981 DOI: 10.1126/science.ll70261] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
|
59
|
Vitousek PM, Naylor R, Crews T, David MB, Drinkwater LE, Holland E, Johnes PJ, Katzenberger J, Martinelli LA, Matson PA, Nziguheba G, Ojima D, Palm CA, Robertson GP, Sanchez PA, Townsend AR, Zhang FS. Nutrient Imbalances in Agricultural Development. Science 2009; 324:1519-20. [DOI: 10.1126/science.1170261] [Citation(s) in RCA: 893] [Impact Index Per Article: 59.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
60
|
|
61
|
Cifelli P, Lewis S, Erskine P, Holland E, Williams P, Camara M, Knox A, Smyth A. An RCT of macerated garlic oil in patients with CF & chronic Pseudomonas aeruginosa. J Cyst Fibros 2008. [DOI: 10.1016/s1569-1993(08)60261-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
62
|
Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Panageas K, Gu B, Rao J, Fleisher M, Holland E, DeAngelis LM, Hormigo A. A longitudinal prospective study of YKL-40 and matrix metalloproteinase-9 (MMP-9) as serum tumor markers in gliomas. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.2038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
63
|
Holland E. Marquardt's Phi mask: pitfalls of relying on fashion models and the golden ratio to describe a beautiful face. Aesthetic Plast Surg 2008; 32:200-8. [PMID: 18175168 DOI: 10.1007/s00266-007-9080-z] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND Stephen Marquardt has derived a mask from the golden ratio that he claims represents the "ideal" facial archetype. Many have found his mask convincing, including cosmetic surgeons. However, Marquardt's mask is associated with numerous problems. The method used to examine goodness of fit with the proportions in the mask is faulty. The mask is ill-suited for non-European populations, especially sub-Saharan Africans and East Asians. The mask also appears to approximate the face shape of masculinized European women. Given that the general public strongly and overwhelmingly prefers above average facial femininity in women, white women seeking aesthetic facial surgery would be ill-advised to aim toward a better fit with Marquardt's mask. This article aims to show the proper way of assessing goodness of fit with Marquardt's mask, to address the shape of the mask as it pertains to masculinity-femininity, and to discuss the broader issue of an objective assessment of facial attractiveness. METHODS Generalized Procrustes analysis is used to show how goodness of fit with Marquardt's mask can be assessed. Thin-plate spline analysis is used to illustrate visually how sample faces, including northwestern European averages, differ from Marquardt's mask. RESULTS Marquardt's mask best describes the facial proportions of masculinized white women as seen in fashion models. CONCLUSIONS Marquardt's mask does not appear to describe "ideal" face shape even for white women because its proportions are inconsistent with the optimal preferences of most people, especially with regard to femininity.
Collapse
|
64
|
Liu Y, Yeh N, Zhu XH, Leversha M, Cordon-Cardo C, Ghossein R, Singh B, Holland E, Koff A. Somatic cell type specific gene transfer reveals a tumor-promoting function for p21(Waf1/Cip1). EMBO J 2007; 26:4683-93. [PMID: 17948060 PMCID: PMC2048756 DOI: 10.1038/sj.emboj.7601886] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2007] [Accepted: 09/19/2007] [Indexed: 02/08/2023] Open
Abstract
How proteins participate in tumorigenesis can be obscured by their multifunctional nature. For example, depending on the cellular context, the cdk inhibitors can affect cell proliferation, cell motility, apoptosis, receptor tyrosine kinase signaling, and transcription. Thus, to determine how a protein contributes to tumorigenesis, we need to evaluate which functions are required in the developing tumor. Here we demonstrate that the RCAS/TvA system, originally developed to introduce oncogenes into somatic cells of mice, can be adapted to allow us to define the contribution that different functional domains make to tumor development. Studying the development of growth-factor-induced oligodendroglioma, we identified a critical role for the Cy elements in p21, and we showed that cyclin D1T286A, which accumulates in the nucleus of p21-deficient cells and binds to cdk4, could bypass the requirement for p21 during tumor development. These genetic results suggest that p21 acts through the cyclin D1–cdk4 complex to support tumor growth, and establish the utility of using a somatic cell modeling system for defining the contribution proteins make to tumor development.
Collapse
|
65
|
Hottinger AF, Gu B, Fleisher M, Abrey LE, Holland E, Deangelis LM, Hormigo A. Prospective analysis of expression of circulating levels of matrix metalloproteinase-9 (MMP-9) in the serum of patients with primary central nervous system lymphoma (PCNSL). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.1532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1532 Background: Matrix metalloproteinases have been associated with angiogenesis, tumor infiltration and metastases formation in systemic lymphoma. Disease status in PCNSL is determined by brain MRI; however it may be inconclusive and non-invasive tests to evaluate disease status would be useful. This study was designed to determine whether circulating levels of MMP-9 could be related to disease status in PCNSL. Methods: Circulating levels of MMP-9 were determined by ELISA and correlated with disease status assessed by MRI in a prospective longitudinal study. The disease status was classified as no evidence of disease (CR) versus active disease (AD). Results: We enrolled 18 PCNSL patients and obtained 93 blood samples (median 6 per patient, range 1–10) from August 2002 to December 2005. When in CR (12 patients, 59 samples), the mean MMP-9 level was 205.5 ± 19.1 ng/ml (median 162.3 ng/ml, range: 35.9–649.1 ng/ml). MMP-9 levels were significantly higher in AD (16 patients, 34 samples), with a mean MMP-9 of 638.2 ± 140.7 ng/ml (median 287.5 ng/ml, range 24.7–3340.6 ng/ml) (p = 0.0001). Paired samples obtained before and after therapy were obtained in 10 patients. Patients in AD had a mean of 1223.9 ± 336.5 ng/ml (median 770.1 ng/ml, range 284.1–3340.6 ng/ml) before treatment and levels fell to a mean of 143.5 ± 38.4 ng/ml (median 86.7 ng/ml, range 28.1–356.5 ng/ml) (p = 0.005) when CR was reached. During follow-up, 4 of the 18 patients developed recurrent disease (total 5 recurrences). MMP-9 levels increased from 154.22 ± 34.9 ng/ml (median 162.4 ng/ml, range 64.5–260.3 ng/ml) to 324.4 ± 98.5 ng/ml (median 251.5 ng/ml, range: 159.5–709.7 ng/ml) (p = 0.14) at relapse. Conclusions: PCNSL patients in CR have circulating MMP-9 levels that are significantly lower than in patients with AD. A significant drop in MMP-9 was seen after treatment compared to baseline. MMP-9 levels increased with disease recurrence but did not reach statistical significance in this small population. MMP-9 has the potential to complement neuroimaging to confirm remission or progression. No significant financial relationships to disclose.
Collapse
|
66
|
White LJ, Dressendorfer RH, Holland E, McCoy SC, Ferguson MA. Increased Caloric Intake Soon after Exercise in Cold Water. Int J Sport Nutr Exerc Metab 2005; 15:38-47. [PMID: 15902988 DOI: 10.1123/ijsnem.15.1.38] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
We examined the acute effect of cold-water temperature on post-exercise energy intake (EI) for 1 h. In a randomized, crossover design, 11 men (25.6 ± 5 y) exercised for 45 min on a submersed cycle ergometer at 60 ± 2% VO2max in 33°C (neutral) and 20° (cold) water temperatures, and also rested for 45 min (control). Energy expenditure (EE) was determined using indirect calorimetry before, during, and after each condition. Following exercise or rest, subjects had free access to a standard assortment of food items of known caloric value. EE was similar for the cold and neutral water conditions, averaging 505 ± 22 (± standard deviation) and 517 ± 42 kcal, respectively (P = NS). EI after the cold condition averaged 877 ± 457 kcal, 44% and 41% higher (P < 0.05) than for the neutral and resting conditions, respectively. Cold-water temperature thus stimulated post-exercise EI. Water temperature warrants consideration in aquatic programs designed for weight loss.
Collapse
|
67
|
Weiss WA, Israel M, Cobbs C, Holland E, James CD, Louis DN, Marks C, McClatchey AI, Roberts T, Van Dyke T, Wetmore C, Chiu IM, Giovannini M, Guha A, Higgins RJ, Marino S, Radovanovic I, Reilly K, Aldape K. Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene 2002; 21:7453-63. [PMID: 12386807 DOI: 10.1038/sj.onc.1205936] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2002] [Revised: 08/05/2002] [Accepted: 08/05/2002] [Indexed: 11/09/2022]
Abstract
The Mouse Models of Cancer Consortium of the NCI sponsored a meeting of neuropathologists and veterinary pathologists in New York City in November of 2000. A rapidly growing number of genetically engineered mice (GEM) predisposed to tumors of the nervous system have led to a concomitant need for neuropathological evaluation and validation of these models. A panel of 13 pathologists reviewed material representing most of the available published and unpublished GEM models of medulloblastoma, primitive neuroectodermal tumor, astrocytoma, oligodendroglioma, mixed glioma, and tumors of the peripheral nerve. The GEM tumors were found to have many similarities and some distinct differences with respect to human disease. After review of the biology and pathology for all models presented, participants were split into groups reflective of clinical expertise in human pathology, tumor biology, neuroimaging, or treatment/intervention. Recommendations were made detailing an extensive and complete neuropathological characterization of animals. Importance was placed on including information on strains, tumor clonality, and examination for genetic mutation or altered gene expression characteristics of the corresponding human malignancy. Specific proposals were made to incorporate GEM models in emerging neuroradiological modalities. Recommendations were also made for preclinical validation of these models in cancer therapeutics, and for incorporation of surrogate markers of tumor burden to facilitate preclinical evaluation of new therapies.
Collapse
|
68
|
Van Rompaey L, Holland E, Grosveld G. TEL Induces Aggregation in Transformed Cells and Induces Tube Formation in NIH3T3-UCLA Cells. Biochem Biophys Res Commun 2002; 291:820-8. [PMID: 11866439 DOI: 10.1006/bbrc.2002.6513] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
TEL/ETV6 is the frequent target of translocations associated with lymphoid and myeloid leukemias and solid tumors. We show that TEL induces aggregation of immortalized and transformed fibroblasts, endothelial cells and astrocytes. These aggregates form cellular cords in NIH3T3-UCLA by a cell autonomous process, which occurs when the monolayer is made up of over 75% of cells expressing exogenous TEL. Cords with a diameter of 15-25 microm contain a lumen and occur as tube structures. The possible relevance for vasculogenic mimicry is discussed. By contrast TEL did not induce aggregation of regular NIH3T3 cells, an effect that could only be induced by co-expression of oncogenic RAS/Lys12. Also transduction of TEL and RAS retroviral vectors into the endothelial MS1 cell line and TEL alone in the highly transformed glioblastoma cell lines EH-A and EH-B resulted in extensive aggregation. Thus, the induction of cellular aggregation by TEL correlates with transformation.
Collapse
|
69
|
Knox AJ, Corbett L, Stocks J, Holland E, Zhu YM, Pang L. Human airway smooth muscle cells secrete vascular endothelial growth factor: up-regulation by bradykinin via a protein kinase C and prostanoid-dependent mechanism. FASEB J 2001; 15:2480-8. [PMID: 11689473 DOI: 10.1096/fj.01-0256com] [Citation(s) in RCA: 100] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Bronchial vascular remodeling is an important feature of the pathology of chronic asthma, but the responsible mechanisms and main sources of angiogenic factors are unclear. Here we report that human airway smooth muscle cells express vascular endothelial growth factor (VEGF)121, 165, 189, 206 splice variants and secrete VEGF protein constitutively. VEGF protein secretion was increased by the proinflammatory asthma mediator bradykinin through post-transcriptional mechanisms. Bradykinin-induced VEGF secretion was dependent on the B2 bradykinin receptor, activation of protein kinase C, and generation of endogenous prostanoids. This is the first report that bradykinin can increase VEGF secretion in any biological system and the first to show that airway smooth muscle cells produce VEGF. Our results suggest a novel role for human airway smooth muscle in contributing to bronchial mucosal angiogenesis in chronic asthma by secretion of VEGF and suggest a wider role for mesenchymal cell products in mediating angiogenesis in inflammatory and allergic diseases.
Collapse
MESH Headings
- Adult
- Arachidonic Acid/pharmacology
- Bradykinin/analogs & derivatives
- Bradykinin/pharmacology
- Bradykinin Receptor Antagonists
- Cell Survival/drug effects
- Cells, Cultured
- Cyclic AMP/metabolism
- Cyclooxygenase Inhibitors/pharmacology
- Dinoprostone/pharmacology
- Dinoprostone/physiology
- Dose-Response Relationship, Drug
- Endothelial Growth Factors/genetics
- Endothelial Growth Factors/metabolism
- Enzyme Inhibitors/pharmacology
- Female
- Gene Expression
- Humans
- Indomethacin/pharmacology
- Lymphokines/drug effects
- Lymphokines/genetics
- Lymphokines/metabolism
- Male
- Middle Aged
- Muscle, Smooth, Vascular/cytology
- Muscle, Smooth, Vascular/drug effects
- Muscle, Smooth, Vascular/metabolism
- Naphthalenes/pharmacology
- Nitrobenzenes/pharmacology
- Prostaglandins/pharmacology
- Prostaglandins/physiology
- Protein Isoforms/genetics
- Protein Kinase C/antagonists & inhibitors
- Protein Kinase C/metabolism
- RNA/drug effects
- RNA/genetics
- RNA/metabolism
- Receptor, Bradykinin B2
- Receptors, Bradykinin/physiology
- Reverse Transcriptase Polymerase Chain Reaction
- Sulfonamides/pharmacology
- Time Factors
- Trachea/cytology
- Trachea/drug effects
- Trachea/metabolism
- Up-Regulation
- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factors
Collapse
|
70
|
Rao G, Fults D, Holland E. 725 Somatic Cell Gene Transfer into Model PNET in NTV-a Transgenic Mice. Neurosurgery 2001. [DOI: 10.1227/00006123-200108000-00089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
71
|
Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95:190-8. [PMID: 11780887 DOI: 10.3171/jns.2001.95.2.0190] [Citation(s) in RCA: 1945] [Impact Index Per Article: 84.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
OBJECT The extent of tumor resection that should be undertaken in patients with glioblastoma multiforme (GBM) remains controversial. The purpose of this study was to identify significant independent predictors of survival in these patients and to determine whether the extent of resection was associated with increased survival time. METHODS The authors retrospectively analyzed 416 consecutive patients with histologically proven GBM who underwent tumor resection at the authors' institution between June 1993 and June 1999. Volumetric data and other tumor characteristics identified on magnetic resonance (MR) imaging were collected prospectively. CONCLUSIONS Five independent predictors of survival were identified: age, Karnofsky Performance Scale (KPS) score, extent of resection, and the degree of necrosis and enhancement on preoperative MR imaging studies. A significant survival advantage was associated with resection of 98% or more of the tumor volume (median survival 13 months, 95% confidence interval [CI] 11.4-14.6 months), compared with 8.8 months (95% CI 7.4-10.2 months; p < 0.0001) for resections of less than 98%. Using an outcome scale ranging from 0 to 5 based on age, KPS score, and tumor necrosis on MR imaging, we observed significantly longer survival in patients with lower scores (1-3) who underwent aggressive resections, and a trend toward slightly longer survival was found in patients with higher scores (4-5). Gross-total tumor resection is associated with longer survival in patients with GBM, especially when other predictive variables are favorable.
Collapse
|
72
|
Pacala SW, Hurtt GC, Baker D, Peylin P, Houghton RA, Birdsey RA, Heath L, Sundquist ET, Stallard RF, Ciais P, Moorcroft P, Caspersen JP, Shevliakova E, Moore B, Kohlmaier G, Holland E, Gloor M, Harmon ME, Fan SM, Sarmiento JL, Goodale CL, Schimel D, Field CB. Consistent land- and atmosphere-based U.S. carbon sink estimates. Science 2001; 292:2316-20. [PMID: 11423659 DOI: 10.1126/science.1057320] [Citation(s) in RCA: 211] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
For the period 1980-89, we estimate a carbon sink in the coterminous United States between 0.30 and 0.58 petagrams of carbon per year (petagrams of carbon = 10(15) grams of carbon). The net carbon flux from the atmosphere to the land was higher, 0.37 to 0.71 petagrams of carbon per year, because a net flux of 0.07 to 0.13 petagrams of carbon per year was exported by rivers and commerce and returned to the atmosphere elsewhere. These land-based estimates are larger than those from previous studies (0.08 to 0.35 petagrams of carbon per year) because of the inclusion of additional processes and revised estimates of some component fluxes. Although component estimates are uncertain, about one-half of the total is outside the forest sector. We also estimated the sink using atmospheric models and the atmospheric concentration of carbon dioxide (the tracer-transport inversion method). The range of results from the atmosphere-based inversions contains the land-based estimates. Atmosphere- and land-based estimates are thus consistent, within the large ranges of uncertainty for both methods. Atmosphere-based results for 1980-89 are similar to those for 1985-89 and 1990-94, indicating a relatively stable U.S. sink throughout the period.
Collapse
|
73
|
Kennedy RH, Hogan RN, Brown P, Holland E, Johnson RT, Stark W, Sugar J. Eye banking and screening for Creutzfeldt-Jakob disease. ARCHIVES OF OPHTHALMOLOGY (CHICAGO, ILL. : 1960) 2001; 119:721-6. [PMID: 11346399 DOI: 10.1001/archopht.119.5.721] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
OBJECTIVES To quantify the risk of Creutzfeldt-Jakob disease (CJD) among cornea donors, evaluate supplemental screening strategies, and address concerns about the adequacy of current methods of screening tissue donors in the United States. METHODS Reported data on deaths due to CJD and from all causes were used to estimate the rate of CJD among cornea donors. The impact of increased screening on risk of CJD and donor supply was evaluated. RESULTS Only 1.3 of the approximately 45 000 cornea donors in the United States each year might be expected to have CJD. Most of the estimated risk (91%) is due to preclinical (asymptomatic) disease and therefore could not be eliminated by screening for signs or symptoms. If only the highest-risk age group (60 to 69 years) were screened and specificity were 90%, more than 21 000 otherwise acceptable donors would incorrectly be excluded over a period of 17.5 years to correctly exclude a single donor with symptomatic CJD. CONCLUSIONS Currently, the risk of CJD transmission following cornea transplantation is remarkably low. Screening for symptoms of CJD would have minimal impact on safety, but would reduce donor supply and likely result in many patients not receiving needed treatment.
Collapse
|
74
|
Fong CY, Pang L, Holland E, Knox AJ. TGF-beta1 stimulates IL-8 release, COX-2 expression, and PGE(2) release in human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2000; 279:L201-7. [PMID: 10893219 DOI: 10.1152/ajplung.2000.279.1.l201] [Citation(s) in RCA: 90] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
We have recently shown that endogenous prostanoids are critical in bradykinin-stimulated interleukin (IL)-8 release from human airway smooth muscle (ASM) cells. In this study, we tested the ability of transforming growth factor (TGF)-beta1 to stimulate IL-8 release, cyclooxygenase (COX)-2 expression and PGE(2) generation in cultured human ASM cells and explored the role of COX products and COX-2 induction on IL-8 release. TGF-beta1 stimulated IL-8 release, COX-2 induction, and PGE(2) generation in a concentration- and time-dependent manner. Maximal IL-8 release was achieved with 10 ng/ml of TGF-beta1 after 16 h of incubation, which was inhibited by the transcription inhibitor actinomycin D and the corticosteroid dexamethasone but was not affected by the nonselective COX inhibitor indomethacin and the selective COX-2 inhibitor NS-398 despite their inhibition on TGF-beta1-induced PGE(2) release. These results show for the first time that TGF-beta1 stimulates IL-8 release, COX-2 induction, and PGE(2) generation in human ASM cells and that PGE(2) generation is not critical for TGF-beta1-induced IL-8 release. These findings suggest that TGF-beta1 may play an important role in the pathophysiology of asthma.
Collapse
|
75
|
Range SP, Pang L, Holland E, Knox AJ. Selectivity of cyclo-oxygenase inhibitors in human pulmonary epithelial and smooth muscle cells. Eur Respir J 2000; 15:751-6. [PMID: 10780769 DOI: 10.1034/j.1399-3003.2000.15d20.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Cyclo-oxygenase (COX) inhibitors may have a role in reducing inflammation in asthma and other pulmonary diseases. COX inhibitors have different selectivities for the two COX isoenzymes (COX 1 and COX 2) which vary between purified enzyme and intact cell preparations. The relative selectivity of COX inhibitors has not been studied in human airway cells. A number of COX inhibitors in cultured human airway cells were compared which exclusively express either COX 1 (primary degree cultured human airway smooth muscle (HASM) cells) or COX 2 (A549 pulmonary epithelial cell-line) as measured by Western blotting. COX activity was assayed by prostaglandin (PG)E2 production following 30 min incubation with 5 mM arachidonic acid. COX activity in both cell types was similar; HASM cells 92.2+/-12.1 ng PGE2 x mg-1 protein, A549 cells 87.7+/-24.4 ng PGE2 mg-1 protein. In HASM cells the median inhibitory concentration (IC50) was >10-5 M for nimesulide, 3.2 x 10-6 M for N-(2-cyclohexyloxy-4-nitrophenyl)-methanesulphonamide (NS398), 1.8 x 10-8 M for flurbiprofen, 6.7 x 10-9 M for indomethacin and >10-5 M for aspirin. In A549 cells the IC50 was 1.8 x 10-9M for nimesulide, 4.1 x 10-9 M for NS398,6.2 x 10-10 M for flurbiprofen, 1.3 x 10-8 M for indomethacin and >10-5 M for aspirin. Sodium valerate had no effect in either HASM or A549 cells. The COX 2:COX 1 selectivity ratio (COX 2 IC50/COX I IC50) was <0.0001 for nimesulide, 0.001 for NS398, 0.03 for flurbiprofen and 1.9 for indomethacin. In conclusion the present study has shown that cyclo-oxygenase inhibitors have a range of selectivities for cyclo-oxygenase 1 and cyclo-oxygenase 2 in intact human airway cells. The relative cyclo-oxygenase 2 selectivity of N-(2-cyclohexyloxy-4-nitrophenyl)-methanesulphonamide and nimesulide may have implications for the treatment of asthma and other inflammatory pulmonary diseases.
Collapse
|